Amikacin Liposome Inhalation Suspension as  a Treatment Option for Refractory Nontuberculous Mycobacterial Lung Disease Caused by Mycobacterium avium Complex

We read with much interest the review by Shulha et  al.1 The article is a comprehensive and well-written overview of pharmacological treatment approaches of nontuberculous mycobacterial (NTM) diseases. Table 2 (titled “NTM Medication Dosing, Adverse Effects, and Recommended Monitoring”), however, did not include an approved treatment option fo r NTM lung disease caused by Mycobacterium avium complex (MAC), namely, amikacin liposome inhalation suspension (ALIS; Arikayce). Amikacin liposome inhalation suspension is the first Food and Drug Administration (FDA)–approved medication with a specific indication for refractory MAC lung disease ( MAC-LD).

Source: Mayo Clinic Proceedings - December 31, 2019 Category: Internal Medicine Authors: Colin Swenson, Angelo Del Parigi Tags: Letter to the editor Source Type: research